131.52
price down icon0.81%   -1.07
after-market Handel nachbörslich: 131.46 -0.06 -0.05%
loading
Schlusskurs vom Vortag:
$132.59
Offen:
$133.05
24-Stunden-Volumen:
976.95K
Relative Volume:
0.68
Marktkapitalisierung:
$19.27B
Einnahmen:
$9.82B
Nettoeinkommen (Verlust:
$1.48B
KGV:
12.98
EPS:
10.13
Netto-Cashflow:
$2.30B
1W Leistung:
+5.22%
1M Leistung:
+3.31%
6M Leistung:
-10.04%
1J Leistung:
-42.17%
1-Tages-Spanne:
Value
$130.13
$133.05
1-Wochen-Bereich:
Value
$121.05
$133.05
52-Wochen-Spanne:
Value
$110.03
$219.44

Biogen Inc Stock (BIIB) Company Profile

Name
Firmenname
Biogen Inc
Name
Telefon
(781) 464-2000
Name
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
7,605
Name
Twitter
@biogen
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
BIIB's Discussions on Twitter

Vergleichen Sie BIIB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
BIIB
Biogen Inc
131.52 19.43B 9.82B 1.48B 2.30B 10.13
Drug Manufacturers - General icon
LLY
Lilly Eli Co
812.69 723.06B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
168.30 407.97B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.28 337.08B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.70 227.39B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
71.70 314.28B 43.59B 15.04B 10.74B 3.3766

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-21 Fortgesetzt Truist Hold
2025-04-28 Herabstufung HSBC Securities Buy → Hold
2025-04-04 Herabstufung Argus Buy → Hold
2025-02-11 Eingeleitet Bernstein Mkt Perform
2025-01-02 Herabstufung Piper Sandler Overweight → Neutral
2024-12-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-12-16 Herabstufung Stifel Buy → Hold
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-12-09 Herabstufung Jefferies Buy → Hold
2024-11-18 Herabstufung Needham Buy → Hold
2024-11-15 Eingeleitet Wolfe Research Peer Perform
2024-11-14 Eingeleitet Citigroup Neutral
2024-10-31 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-02-14 Bestätigt Needham Buy
2024-02-14 Herabstufung Wells Fargo Overweight → Equal Weight
2024-01-24 Herabstufung UBS Buy → Neutral
2023-12-20 Fortgesetzt Cantor Fitzgerald Overweight
2023-12-07 Hochstufung Raymond James Mkt Perform → Outperform
2023-09-06 Eingeleitet HSBC Securities Buy
2023-07-27 Eingeleitet Scotiabank Sector Outperform
2023-07-24 Bestätigt UBS Buy
2023-05-01 Hochstufung Guggenheim Neutral → Buy
2023-04-17 Hochstufung Piper Sandler Neutral → Overweight
2022-10-26 Hochstufung Goldman Neutral → Buy
2022-10-13 Hochstufung Stifel Hold → Buy
2022-10-07 Hochstufung Argus Hold → Buy
2022-09-28 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-09-28 Hochstufung Mizuho Neutral → Buy
2022-09-28 Hochstufung Robert W. Baird Neutral → Outperform
2022-04-18 Hochstufung Wells Fargo Equal Weight → Overweight
2022-03-08 Herabstufung Stifel Buy → Hold
2022-03-03 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-02-04 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-04 Bestätigt Barclays Equal Weight
2022-02-04 Bestätigt BofA Securities Neutral
2022-02-04 Bestätigt Cowen Outperform
2022-02-04 Bestätigt Morgan Stanley Overweight
2022-02-04 Bestätigt Needham Buy
2022-02-04 Bestätigt Oppenheimer Outperform
2022-02-04 Bestätigt RBC Capital Mkts Sector Perform
2022-02-04 Bestätigt Robert W. Baird Neutral
2022-02-04 Bestätigt Wedbush Neutral
2022-02-04 Bestätigt Wells Fargo Equal Weight
2022-02-04 Bestätigt Wolfe Research Peer Perform
2022-01-13 Herabstufung Guggenheim Buy → Neutral
2022-01-12 Herabstufung Piper Sandler Overweight → Neutral
2021-12-10 Fortgesetzt Raymond James Mkt Perform
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-09-23 Eingeleitet Needham Buy
2021-06-18 Hochstufung Piper Sandler Neutral → Overweight
2021-06-14 Bestätigt Truist Buy
2021-06-11 Hochstufung Bernstein Mkt Perform → Outperform
2021-06-10 Hochstufung UBS Neutral → Buy
2021-06-08 Hochstufung Atlantic Equities Underweight → Neutral
2021-06-08 Bestätigt Barclays Equal Weight
2021-06-08 Hochstufung Citigroup Sell → Neutral
2021-06-08 Bestätigt H.C. Wainwright Buy
2021-06-08 Bestätigt Jefferies Buy
2021-06-08 Bestätigt Morgan Stanley Overweight
2021-06-08 Bestätigt RBC Capital Mkts Sector Perform
2021-06-08 Hochstufung Robert W. Baird Underperform → Neutral
2021-06-08 Bestätigt Stifel Buy
2021-06-08 Hochstufung William Blair Mkt Perform → Outperform
2021-06-07 Hochstufung BofA Securities Underperform → Neutral
2021-06-07 Hochstufung Cowen Market Perform → Outperform
2021-06-07 Hochstufung Raymond James Underperform → Mkt Perform
2021-02-05 Herabstufung DZ Bank Buy → Hold
2021-01-29 Hochstufung Stifel Hold → Buy
2020-11-10 Hochstufung DZ Bank Hold → Buy
2020-11-09 Herabstufung Atlantic Equities Neutral → Underweight
2020-11-09 Herabstufung BofA Securities Neutral → Underperform
2020-11-09 Herabstufung Cowen Outperform → Market Perform
2020-11-09 Bestätigt H.C. Wainwright Buy
2020-11-04 Hochstufung BofA Securities Underperform → Neutral
2020-11-04 Hochstufung Jefferies Hold → Buy
2020-11-04 Hochstufung Wells Fargo Equal Weight → Overweight
2020-10-28 Eingeleitet UBS Neutral
2020-07-27 Hochstufung Morgan Stanley Underweight → Overweight
2020-06-22 Herabstufung Barclays Overweight → Equal Weight
2020-06-22 Bestätigt RBC Capital Mkts Sector Perform
2020-06-09 Herabstufung Bernstein Outperform → Mkt Perform
2020-04-23 Herabstufung Citigroup Neutral → Sell
2020-04-23 Herabstufung Raymond James Mkt Perform → Underperform
2020-03-31 Eingeleitet Wolfe Research Peer Perform
2020-02-27 Eingeleitet Barclays Overweight
2020-01-27 Hochstufung Canaccord Genuity Hold → Buy
2019-12-13 Hochstufung Credit Suisse Underperform → Neutral
2019-12-02 Herabstufung Robert W. Baird Neutral → Underperform
Alle ansehen

Biogen Inc Aktie (BIIB) Neueste Nachrichten

pulisher
Jul 26, 2025

Biogen (NASDAQ:BIIB) Stock Acquired Rep. Robert Bresnahan, Jr. - MarketBeat

Jul 26, 2025
pulisher
Jul 26, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat

Jul 26, 2025
pulisher
Jul 26, 2025

Pacer Advisors Inc. Has $185.08 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 26, 2025
pulisher
Jul 26, 2025

Victory Capital Management Inc. Has $17.07 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 26, 2025
pulisher
Jul 26, 2025

Envestnet Asset Management Inc. Buys 5,926 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 26, 2025
pulisher
Jul 25, 2025

Is Biogen Inc. a good long term investmentFree Stock Market Knowledge Sharing - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Biogen is the latest entrant in NC’s corporate investment surge - Carolina Journal

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Biogen Inc. stock priceTurbocharged investment results - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying Biogen Inc. stock nowFree Stock Market Trend Analysis - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Lilly Gets Limited European Backing for Alzheimer’s Drug - Bloomberg.com

Jul 25, 2025
pulisher
Jul 25, 2025

Biogen Inc. Announces Positive Opinion from EMA for ZURZUVAE® as First Marketing Authorization for Postpartum Depression Treatment in the EU - Quiver Quantitative

Jul 25, 2025
pulisher
Jul 25, 2025

Biogen Inc. - Via Ritzau

Jul 25, 2025
pulisher
Jul 25, 2025

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Zacks Research Has Negative Outlook for Biogen Q2 Earnings - MarketBeat

Jul 25, 2025
pulisher
Jul 25, 2025

Lilly (LLY) Gets Limited European Backing for Alzheimer’s Disease Drug - Bloomberg.com

Jul 25, 2025
pulisher
Jul 25, 2025

Truist Financial Begins Coverage on Biogen (NASDAQ:BIIB) - MarketBeat

Jul 25, 2025
pulisher
Jul 25, 2025

Universal Beteiligungs und Servicegesellschaft mbH Acquires 4,594 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Biogen Inc. stockExponentially increasing returns - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

When is the best time to buy Biogen Inc. stockFast-track wealth growth - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Genentech Seeks Win After $122M Biogen Royalties Mistrial - Law360

Jul 24, 2025
pulisher
Jul 24, 2025

Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Recipients - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Biogen, Zydus Settle Patent Suit Over Copies of MS Drug Vumerity - Bloomberg Law News

Jul 24, 2025
pulisher
Jul 24, 2025

Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

Biogen (BIIB) Projected to Post Earnings on Thursday - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Allianz Asset Management GmbH Has $91.38 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 24, 2025
pulisher
Jul 23, 2025

Biogen Inc. Stock Analysis and ForecastExceptional gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Biogen to invest $2 billion in RTP, open new factory in 2025 - WRAL.com

Jul 23, 2025
pulisher
Jul 23, 2025

(BIIB) On The My Stocks Page - news.stocktradersdaily.com

Jul 23, 2025
pulisher
Jul 23, 2025

Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

How the Recombinant Dna Technology Market Will Evolve by 2032 - openPR.com

Jul 23, 2025
pulisher
Jul 23, 2025

Citi Remains a Hold on Biogen (BIIB) - The Globe and Mail

Jul 23, 2025
pulisher
Jul 23, 2025

Will Major North Carolina Expansion Change Biogen's (BIIB) Narrative? - simplywall.st

Jul 23, 2025
pulisher
Jul 22, 2025

Beacon Investment Advisory Services Inc. Sells 3,529 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division - Benzinga

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen, one of the largest employers in RTP, plans $2B investment in the Triangle - Axios

Jul 22, 2025
pulisher
Jul 22, 2025

How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Los Angeles Capital Management LLC Takes $5.93 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

Spinal Muscular Atrophy Treatment Market Growth Accelerated - openPR.com

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen: Hold Rating Amid Stagnant Growth and Uncertain Prospects - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen to invest further $2bn in North Carolina’s Research Triangle Park - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance Biotherapeutics shares rise 2.41% premarket after Biogen's $2 billion investment in North Carolina manufacturing. - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

AustralianSuper Pty Ltd Buys New Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 22, 2025
pulisher
Jul 21, 2025

Biogen investing $2B to expand operations in RTP - ABC11

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen's Alzheimer's Innovation Pipeline: Lecanemab and BIIB080 as Catalysts for Long-Term Growth - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi - yahoo.co

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - Biogen

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Breakthrough: 48-Month LEQEMBI Results Plus Game-Changing Subcutaneous Alzheimer's Treatment Option - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 21, 2025

Finanzdaten der Biogen Inc-Aktie (BIIB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general SNY
$50.37
price up icon 0.48%
drug_manufacturers_general PFE
$24.79
price down icon 2.21%
$116.20
price up icon 2.65%
$306.58
price down icon 0.64%
drug_manufacturers_general MRK
$84.71
price up icon 0.71%
drug_manufacturers_general NVO
$71.70
price up icon 1.37%
Kapitalisierung:     |  Volumen (24h):